PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 20260 citationsOpen Access

Jak Inhibitors for Treating T-Cell Lymphomas: Evidence and Future Directions

JAK Inhibitors in the Treatment of T-Cell Lymphomas: Current Evidence and Future Directions

View Full Paper

Authors

GTGardenia TazaNANaveed AhmedJVJohn L. Vaughn

Discussion

Loading...

Member takes

Overview

This review summarizes current evidence for JAK inhibitors treating T-cell lymphomas, indicating promising future research opportunities.

Key Points

  • The review aims to summarize evidence supporting JAK inhibitors for treating T-cell lymphomas and identify future research areas.
  • Reviewed literature on JAK inhibitors in T-cell lymphomas
  • Highlighted specific JAK inhibitors like ruxolitinib and their clinical benefits
  • Discussed ongoing clinical trials for newer agents
  • Ruxolitinib showed a clinical benefit rate of up to 53% in patients with peripheral T-cell lymphoma (PTCL) with specific mutations
  • Response durations are generally limited, suggesting a need for combination therapies
  • Multiple adverse effects, including cytopenias and infections, have been observed in JAK inhibitor treatments
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Taza et al. (2026) studied this question.

synapsesocial.com/papers/69a67eebf353c071a6f0a937https://doi.org/10.3390/cancers18050799
Ask AI
Helpful
Bookmark
Share
View Full Paper